GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial of bulevirtide for adults with chronic hepatitis ...

OmRx Oncology (OmRx) has commenced a Phase II trial for its OX-4224, targeting individuals with non-small cell lung cancer ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with ABO21009, aimed at treating rheumatoid arthritis (RA ...

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for ...

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.